Richmond ENT Celebrates Cigna Coverage of Neuromark® for Chronic Rhinitis
RICHMOND, VA – September 15, 2025 – Richmond ENT is proud to share that Cigna Healthcare has announced expanded coverage for posterior nasal nerve ablation treatments, including Neuromark®, RhinAer®, and ClariFix®, effective September 15, 2025. This decision removes these advanced therapies from Cigna’s list of “experimental or investigational” procedures, making them fully accessible to more than 15 million members nationwide.
For our patients, this is a major step forward. Chronic rhinitis—whether allergic, vasomotor, or age-related (atrophic)—is a debilitating condition marked by constant congestion, post-nasal drip, drainage, and impaired quality of life. Until recently, many patients were limited to daily sprays, pills, or repeated in-office visits with only partial relief.
Richmond ENT’s role in advancing care
Dr. Michael Armstrong, MD, and Dr. Robert Thomas, MD, of Richmond ENT were honored to serve as a research site for the pivotal randomized clinical trials of Neuromark®. These studies provided key evidence to demonstrate Neuromark’s safety and efficacy in:
-
Allergic rhinitis
-
Vasomotor rhinitis
-
Chronic sinusitis
-
Age-related (atrophic) rhinitis
Through this work, Richmond ENT directly contributed to the body of evidence that helped make this coverage decision possible.
“Being part of the Neuromark clinical trial allowed us to help patients breathe better while also advancing the science,” said Dr. Armstrong. “We are delighted that insurance coverage now allows us to bring this proven therapy to more of our community.”
Why Neuromark®?
While multiple technologies now target the posterior nasal nerve (PNN), Neuromark® stands out for its:
-
Precision: A multi-point radiofrequency system that safely ablates branches of the PNN.
-
Versatility: Effective across multiple rhinitis subtypes.
-
Durability: Clinical trials have shown long-term symptom reduction in congestion and drainage.
Patients undergoing Neuromark® often report a noticeable decrease in nasal blockage and runny nose within weeks, without the side effects of chronic medication or the risks of major surgery.
What this means for patients
With Cigna’s policy update, patients with chronic nasal congestion and drainage who have failed medical therapy can now access Neuromark® treatment as a covered benefit. For many, this means:
-
Fewer prescriptions and less reliance on daily sprays.
-
Relief from constant congestion and drainage.
-
Improved quality of life, sleep, and productivity.
Richmond ENT: Local innovation, national impact
As one of the few practices in Virginia to participate in the pivotal Neuromark® studies, Richmond ENT continues to be at the forefront of research-driven, minimally invasive ENT care.
“Cigna’s decision validates years of clinical research,” said Dr. Thomas. “For our patients, it means we can now offer Neuromark with confidence that their insurance will support them in getting the relief they deserve.”
Learn more
Patients interested in Neuromark® , RhinAer® , or ClariFix® can schedule a consultation with Richmond ENT by calling 804-622-3782 or requesting an appointment online. Our team will help determine the most appropriate option based on your symptoms and history.
For providers: Cigna has removed CPT 31242 (radiofrequency ablation of the posterior nasal nerve) and CPT 31243 (cryoablation of the posterior nasal nerve) from investigational status.